Linked Life Data

19542435

Source:http://linkedlifedata.com/resource/pubmed/id/19542435

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-6-22
pubmed:abstractText
Autoimmunity to type V collagen (col(V)) is a major risk factor for lung allograft rejection. Although col(V)-induced oral tolerance abrogates rejection of minor histoincompatible lung transplants, its ability to prevent rejection of fully MHC incompatible lung allografts is unknown. Rat lung allografts fully incompatible at MHC class I and II loci (Brown Norway (RT1(n))) were transplanted into untreated Wistar Kyoto rat recipients (WKY, RT1(l)), or WKY rats were fed col(V) pretransplantation. To determine whether col(V) enhanced cyclosporine (CsA)-mediated immune suppression, WKY rats were treated with low-dose CsA (5 mg/kg), posttransplant, or oral col(V) plus CsA. The data showed that in contrast to col(V) or CsA, col(V) plus low-dose CsA significantly prevented rejection pathology, down-regulated alloantigen-induced production of IFN-gamma and IL-17A, and suppressed chemotaxis for lung macrophages in allograft bronchoalveolar lavage fluid that was associated with lower local levels of MCP-1 (CCL2). Col(V) plus CsA was associated with alloantigen-induced expression of IL-10 in mediastinal lymph node or splenic T cells, intragraft expression of IL-10 and Foxp3 in perivascular and peribronchiolar mononuclear cells, and constitutive production of IL-10 from allograft alveolar macrophages. These data demonstrate that col(V) enhances low-dose CsA-mediated immune suppression, and suggest a role for oral col(V) in immune modulation in lung transplantation.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1550-6606
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
183
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
237-45
pubmed:dateRevised
2011-4-26
pubmed:meshHeading
pubmed-meshheading:19542435-Administration, Oral, pubmed-meshheading:19542435-Animals, pubmed-meshheading:19542435-Cells, Cultured, pubmed-meshheading:19542435-Coculture Techniques, pubmed-meshheading:19542435-Collagen Type V, pubmed-meshheading:19542435-Cyclosporine, pubmed-meshheading:19542435-Dose-Response Relationship, Immunologic, pubmed-meshheading:19542435-Drug Therapy, Combination, pubmed-meshheading:19542435-Graft Rejection, pubmed-meshheading:19542435-Histocompatibility Antigens, pubmed-meshheading:19542435-Histocompatibility Antigens Class II, pubmed-meshheading:19542435-Histocompatibility Testing, pubmed-meshheading:19542435-Immunosuppressive Agents, pubmed-meshheading:19542435-Lung Transplantation, pubmed-meshheading:19542435-Male, pubmed-meshheading:19542435-Rats, pubmed-meshheading:19542435-Rats, Inbred BN, pubmed-meshheading:19542435-Rats, Inbred WKY, pubmed-meshheading:19542435-Transplantation Tolerance
pubmed:year
2009
pubmed:articleTitle
Type V collagen-induced oral tolerance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts.
pubmed:affiliation
Department of Medicine, Center for Immunobiology, Indiana University School of Medicine, Indianapolis, 46202, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural